MedTrace Logo

CVL237 Tablets for APDS/PASLI

NCT06293716 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-03-05

No results posted yet for this study

Summary

This study was designed to evaluate the efficacy and safety of CVL237 tablets in patients with APDS/PASLI (activated phosphoinositol 3-kinase δ syndrome /p110 delta-activated mutation leading to senescent T cells, lymphadenopathy, and immune deficiency).

Conditions

  • PI3K and P110delta Hyperactivation Syndrome

Interventions

DRUG

CVL237 tablets

CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.

DRUG

CVL237 placebo tablets

CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.

Sponsors & Collaborators

  • Convalife (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-30
Primary Completion
2025-12-29
Completion
2026-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06293716 on ClinicalTrials.gov